

Molecular docking analysis of Withaferin A from *Withania somnifera* with the Glucose regulated protein 78 (GRP78) receptor and the SARS-CoV-2 main protease

HV Sudeep*, K Gouthamchandra & K Shyamprasad

R&D Center for Excellence, Vidya Herbs Pvt. Ltd, #14A, Jigani I phase, Bangalore- 560 105, Karnataka, India; Dr. HV Sudeep; Phone: +91 80-42094158; E-mail: research@vidyaherbs.com; *Corresponding author

Contacts: K Gouthamchandra - bml@vidyaherbs.com; K Shyamprasad - shyamprasad@vidyaherbs.com.

Received April 6, 2020; Revised April 23, 2020; Accepted April 23, 2020; Published May 31, 2020

DOI: 10.6026/97320630016411

Declaration on Publication Ethics:

The authors state that they adhere with COPE guidelines on publishing ethics as described elsewhere at <https://publicationethics.org/>. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

Declaration on official E-mail:

The corresponding author declares that official e-mail from Vidya Herbs (P) Ltd is provided for all authors

Abstract:

Design and development of an effective compound to combat COVID-19 is clearly critical in the current circumstances. Therefore, it is of interest to document the molecular docking analysis data of the cellular receptor Glucose regulated protein 78 (GRP78) with Withaferin A from *Withania somnifera* in the context of COVID-19 pandemic for further consideration. Here, we report the optimal interaction features of withaferin A, artemisinin, curcumin and andrographolide with the GRP78 receptor having low binding energies (-8.7, -7.89, -6.21 and -6.17 kcal/mol respectively) in this report. In order to gain additional insights, the interaction pattern of compounds with SARS-CoV-2 main protease (M_{pro}) was studied.

Key words: COVID-19, GRP78, M_{pro}, Withaferin A

Background:

Novel coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared by the World Health Organization (WHO) as a global

pandemic [1]. SARS-CoV-2 is an additional member of human coronaviruses (HCoVs) namely, NL63, 229E, OC43, HKU1, MERS and SARS. HCoVs have single stranded positive sense RNA that

codes for Structural proteins and non-structural proteins. The structural proteins of HCoV include spike protein, capsid, matrix and envelop. The non-structural proteins are proteases (nsp3, 5 and 12).




Figure 1: Chemical structure of Withaferin A (A), artemisinin (B), curcumin (C) and andrographolide (D).

Development of therapeutic interventions to combat with COVID-19 pandemic depends largely on the understanding of coronavirus spike protein interaction with cell-surface receptors. SARS-CoV-2 invades the human cell via Angiotensin converting enzyme-2 (ACE-2) receptors [2, 3]. In addition to ACE-2 receptor other proteins present on the cell surface SIS known to be recognised by the virus for its entry. Glucose-regulated protein 78 (GRP78) primarily recognized as a protein present in endoplasmic reticulum with chaperone activity may translocate to the plasma membrane under cell stress [4,5]. Once localized to the cell surface GRP78 is prone to viral recognition through the substrate binding domain (SBD) subsequently facilitating the viral entry. Previously Chu et al. reported that GRP78 is a target cell surface receptor of the MERS-CoV spike protein [6]. More recently the binding pattern of spike protein of SARS-CoV-2 with GRP78-SBD has been predicted using computational approach [7].

Coronavirus main protease ($M^{pro}/3CL^{pro}$) is another crucial molecular target in anti-CoV drug discovery research due to its indispensable requirement for viral replication and infection [8]. HCoV Mpro is a cysteine protease, which plays important role in the proteolytic activity during cleavage of viral polyprotein [9,10]. Recently the crystal structure of coronavirus M^{pro} has been solved and publicly available in Protein data bank (PDB).

Several pharmacologically active principles from medicinal plants have been reported to exert antiviral activities [11,12,13]. This study was conceived with a strategy of exploring the natural compounds which may impede the SARS-CoV-2 infection by blocking the viral entry into the host cell or inhibiting the viral polyprotein processing in the cell. In this direction, we have screened several small molecules of herbal origin and considered four major compounds withaferin A, artemisinin, curcumin and andrographolide fitting into our strategy. It is of interest to document the molecular docking analysis data of GRP78 with Withaferin A from *Withania somnifera* in the context of SARS-CoV-2 infection for further consideration.




Figure 2: 3D crystal structures of glucose regulated protein 78 (GRP78) (A) and COVID-19 M^{pro} (B).

Methodology:

Protein structures:

The crystal structures of GRP78 bound to ATP (PDB ID: 5E84) and COVID-19 3CLpro/Mpro (PDB ID: 6LU7) were downloaded in .pdb format from PDB database (<http://www.rcsb.org/>). Chain A of the respective proteins was used for macromolecule preparation. The coordinates of PDB structures were prepared for molecular docking by removing the water ions and ligands using Python molecule viewer. The druggability pocket prediction was performed for the proteins using PockDrug-server [14,15].

Ligand preparation:

We have used the potent pharmacologically active phytochemicals such as withaferin A, artemisinin, curcumin, and andrographolide in this study. The 3D structures of these compounds were obtained from Pubchem [16]. The drug-like properties of the molecules were determined using SWISSADME prediction [17]. The PRODRG server was used to minimise energy of natural compounds and 3D coordinates were prepared.

Molecular docking:

The active site residues in the substrate-binding domain (SBD) of GRP78 were retrieved from the literature [18]. The active site amino

acids of COVID-19 M^{pro} were determined using Discovery studio 4.5. AutoDock tool was utilized to generate grids, calculate dock score and evaluate the conformers of compounds bound in the SBD of GRP78, and active pocket of COVID-19 M^{pro}. The grid maps were centred with box size of 50 × 50 × 50 xyz points at active site residues of the proteins GRP78 (x = 34.386, y = 57.953, z = -29.261) and COVID-19 M^{pro} (x = -11.580, y = 16.427, z = 65.575), and generated with AutoGrid. As per genetic algorithm, all the torsions could rotate during docking. The Lamarckian genetic algorithm and the pseudo-Solis and Wets methods were applied for minimization, using default parameters [19].

Table 1: Drug likeliness of natural compounds

	Compounds			
Lipinski's rule of five	Withaferin A	Artemisinin	Curcumin	Andrographolide
Molecular weight (<500 Da)	470.60	282.33	368.38	350.45
MLog P (<4.15)	2.75	2.62	1.47	1.98
H-Bond donor (5)	2	0	2	3
H-Bond acceptor (<10)	6	5	6	5
Violation	0	0	0	0

Table 2: Pocket druggability prediction of the target proteins

Pockets	Vol. Hull*	Hydroph. Kyte*	Polar Res.*	Aromatic Res.*	Otyr atom	Nb. Res.*	Drugg Prob*	Standard Deviation
GRP78-SBD	6966.5	0.39	0.42	0.03	0.0	40.0	0.93	0.02
COVID-19 M ^{pro}	28941.05	-0.11	0.54	0.13	0.01	161.0	0.97	0.01

Vol. Hull* = Volume Hull; Hydrophob. Kyte* = Hydrophobic Kyte; Polar Res.* = Polar Residues Proportion; Aromatic Res.* = Aromatic Residues Proportion (F,Y,H,W); Drugg Prob* = Druggability Probability; Nb. Res.* = Number of pocket residues

Table 3: Molecular docking analysis of compounds against GRP78 active site

Compound	Binding energy	Ligand efficiency	Inhibition constant (μM)	Intermolecular energy	VDW-H Bond Desolvation energy
Withaferin A	-8.7	-0.26	0.42	-9.89	-9.83
Artemisinin	-7.89	-0.39	1.66	-7.89	-7.81
Curcumin	-6.21	-0.23	28.17	-9.79	-9.74
Andrographolide	-6.17	-0.25	29.9	-7.96	-7.57

Table 4: Molecular docking analysis of compounds against 6LU7

Compound	Binding energy	Ligand efficiency	Inhibition constant (μM)	Intermolecular energy	vdW-H Bond Desolvation energy
Withaferin A	-9.83	-0.29	0.063	-11.02	-10.96
Artemisinin	-8.06	-0.4	1.24	-8.06	-7.95
Curcumin	-6.58	-0.24	15.15	-10.15	-9.99
Andrographolide	-6.49	-0.26	17.58	-8.28	-7.34




Figure 3: Interactions between the GRP78 with Withaferin A (A), artemisinin (B), curcumin (C) and andrographolide (D).

Results and Discussion:

In this study we have screened 25 natural compounds of plant origin for potential interaction with the possible therapeutic targets of SARS-CoV-2 infection. We could observe that few of them have shown appreciable binding affinities with GRP78 and COVID-19 M^{pro}. Hence, we have presented here the detailed molecular docking analysis of four promising candidates. **Figure 1** shows the structures of compounds used for docking studies. We have initially considered predicting the drug like nature of the compounds based on Lipinski's rule of five (molecular weight, polar surface area, lipophilicity, hydrogen bonding and charge) as determined using SWISSADME. We found that all the tested molecules satisfied the rule of five in drug likeness (**Table 1**). Next, we have predicted the druggability of the protein pockets. The average druggability probability of GRP78 and COVID-19 M^{pro} pockets were 0.93 ± 0.02 and 0.97 ± 0.01 respectively indicating the likelihood of the pockets to be considered as druggable (**Table 2**). **Figure 2** shows the 3D structures of target proteins.

We have determined the interactive pattern of test compounds with the SBD of GRP78 using molecular docking analysis. Interestingly, we found appreciable interactions between the active site residues of GRP78 and withanolide A with binding energy of -8.7 kcal/mol at its top-binding pose. Among the tested compounds withaferin A

demonstrated strong interaction ($K_i = 421$ nM) with the binding site (**Table 3**). The molecule was found to have non-covalent interactions with Ile426, Thr428, Thr434 and Phe451 residues of GRP78 (**Figure 3A**). Further we have evaluated the binding prediction of the test compounds against the active site residues of COVID-19 M^{pro} (6LU7). The active site of 6LU7 consists of Thr24, Thr26, Asn142, Phe140, Gly143, His163, Glu166 and His172 residues. From our analysis, it was evident that withaferin A showed higher binding ability (Binding energy = -9.83 kcal/mol, $K_i = 63$ nM) into the active site of protein nevertheless; a noticeable interaction of all tested compounds was observed (**Table 4**). **Figure 4** shows the top binding conformation of withaferin A with the COVID-19 M^{pro} active site.




Figure 4: Interaction of withaferin A with the active site of COVID-19 M^{pro} (PDB: 6LU7).

In this study we have used the molecular docking tool to understand the interactions of natural products with plausible targets of SARS-CoV-2 infection such as host cell receptor GRP78 and COVID-19 M^{pro}. The ability of protein active sites to bind to drug-like molecules with extreme affinity is a major phase of target identification in drug discovery [20]. Our predictions indicated that the selected proteins showed high probability of druggability. Further it was found that the test compounds adhered to the Lipinski's rule of five indicating their improved permeability and drug likeness [21]. Docking studies revealed that withaferin A from *Withania somnifera* showed high affinity with GRP78-SBD. Recently, it has been reported that four regions of SARS-CoV-2 spike protein bind to the SBD of GRP78 for its entry into the host cell [7]. Here we speculate that withaferin A could bind to and block the receptor thereby inhibiting the viral entry. We have also performed docking analysis of the compounds as COVID-19 M^{pro} inhibitors. Proteases are often considered as key targets during the discovery of antiviral drugs as they play vital roles in viral replication and polyprotein

processing [22] Interestingly, withaferin A was superior to the other tested compounds in its binding affinity with the protein active site. Withaferin A is a major active constituent of *W. somnifera*, medicinal herb greatly valued in Ayurveda for several medicinal properties including anti-viral activity [23,24]. This study hypothesises that withaferin A may exert its antiviral property against novel coronavirus SARS-CoV-2 by either blocking the host cell receptor or inhibiting the key viral protease required for its replication in the host cell. **Figure 5** illustrates the schematic overview of withaferin A with the molecular targets (Illustration was created using BioRender tool). Our predictions of its candidature in culminating SARS-CoV-2 infection may contribute to the use of natural products in antiviral therapy against the COVID-19 pandemic.




Figure 5. Schematic overview of proposed mechanism of action with which withaferin may inhibit COVID-19 infectivity. We hypothesise that withaferin A may exert its antiviral property against novel COVID-19 by either blocking the host cell receptor GRP78 or inhibiting the key viral protease 3CLpro/Mpro required for its replication in the host cell. PLpro: Pappain-like protease, 3CLpro/Mpro: 3C-like protease/main protease, RdRp: RNA dependent RNA polymerase, Hel: helicase; S: spike glycoprotein, E: envelop protein, M: membrane protein, N: Nucleocapsid protein.

Conclusion:

We have reported the optimal interaction features of withaferin A with the GRP78 receptor and SARS-CoV-2 Mpro in this study. Further research is required to validate the antiviral properties of withaferin A against COVID-19.

Funding:

No external funding received.

Author contribution:

Conceptualization, KS; experimental design and docking analysis, SHV; writing - original draft preparation, SHV, GK; writing - review and editing, SHV; supervision, KS

Conflict of interest:

Authors declare no conflict of interest.

References:

- [1] Cucinotta D & Vanelli M. *Acta bio-medica: Atenei Parmensis*. 2020 **91**:157 [PMID: 32191675]
- [2] Prabakaran P *et al. Journal of Biological Chemistry*. 2006 **281**:5829 [PMID: 16597622]
- [3] Adedeji AO *et al. Journal of Virology*. 2013 **87**:8017 [PMID: 23678171]
- [4] Lee AS. *Methods*. 2005 **35**:373 [PMID: 15804610]
- [5] Li J & Lee AS. *Current Molecular Medicine*. 2006 **6**:45 [PMID: 16472112]
- [6] Chu H *et al. Journal of Biological Chemistry*. 2018 **293**:11709 [PMID: 29887526]
- [7] Ibrahim IM *et al. Journal of Infection*. 2020 **80**:554 [PMID: 32169481]
- [8] Chen S *et al. Journal of Biological Chemistry*. 2005 **280**:164 [PMID: 15507456]
- [9] Xue X *et al. Journal of Molecular Biology* 2007 **366**:965. [PMID: 17189639]
- [10] Yang H *et al. Proceedings of the National Academy of Sciences of the United States of America*. 2003 **100**:13190 [PMID: 14585926]
- [11] Zakaryan H *et al. Archives of Virology*. 2017 **162**:2539 [PMID: 28547385]
- [12] Seema TM & Thyagarajan SP. *International Journal of Pharmacognosy and Phytochemical Research*. 2016 **8**:1020.
- [13] Jo S *et al. Journal of Enzyme Inhibition and Medicinal Chemistry*. 2020 **35**:145 [PMID: 31724441]
- [14] <http://pockdrug.rpbs.univ-paris-diderot.fr>
- [15] Hussein HA *et al. Nucleic Acids Research*. 2015 **43**:W436 [PMID: 25956651]
- [16] <https://pubchem.ncbi.nlm.nih.gov>
- [17] <http://www.swissadme.ch/>
- [18] Yang J *et al. Structure*. 2015 **23**:2191 [PMID: 26655470]
- [19] Rodriguez A & Infante D. *Network Biology*. 2011 **1**:34.
- [20] Hussein HA *et al. Drug Discovery Today*. 2017 **22**:404 [PMID: 27939283]
- [21] Lipinski CA *et al. Advanced Drug Delivery Reviews*. 2001 **46**:3 [PMID: 11259830]

[22] Chang KO *et al. Viruses*. 2019 **11**:1 [PMID: 30823509]

[23] Grover A. *et al. BMC Genomics*. 2010 **11**:S25 [PMID: 21143809]

[24] Grover A. *et al. BMC Genomics*. 2010 **11**:S15 [PMID: 21143798]

Edited by P Kanguane


Citation: Sudeep *et al. Bioinformation* 16(5): 411-417 (2020)

License statement: This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License

Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article for FREE of cost without open access charges. Comments should be concise, coherent and critical in less than 1000 words.

BIOINFORMATION

Discovery at the interface of physical and biological sciences



since 2005

BIOINFORMATION

Discovery at the interface of physical and biological sciences

indexed in

